Laurent Favre

“I'd like to go back to, I guess, the 2027 early look that you provided, and more thinking about the industry backdrop. So wondering how you've been sort of penciling in price against valuable costs.”

“The first one on the remedy disposals, how does it impact the 600 million cost synergies, please? I understand that the wood part of business may have been base case on the remedy, not necessarily refinished.”

“And Sanjeev, I think you said it all within the first five minutes. But can I dig a little bit deeper in that healthcare comment? Can you give us a sense of how much of a headwind it has been over the last year?”

“I have a question around, I guess, the interplay between volumes and pricing. And I was wondering if you had any sense during Q2 that there was a bit of pull forward as customers jumped ahead of price increases that are coming, I guess, effectively in Q3.”

“Actually, following up on this point of, let's say, pre-buy and then normalization in the second part of Q2, and I'm just wondering, where do you feel we are starting in Q3 in terms of volumes versus underlying demand?”